{"id":"NCT03988426","sponsor":"Octapharma","briefTitle":"Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases","officialTitle":"Clinical Phase 3 Study to Evaluate the Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Primary Immunodeficiency Diseases.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-07","primaryCompletion":"2018-01-26","completion":"2018-01-26","firstPosted":"2019-06-17","resultsPosted":"2020-03-10","lastUpdate":"2020-03-10"},"enrollment":25,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immune Deficiency Disorder"],"interventions":[{"type":"BIOLOGICAL","name":"Octanorm","otherNames":[]}],"arms":[{"label":"Octanorm","type":"EXPERIMENTAL"}],"summary":"Clinical phase 3 study to evaluate the efficacy, tolerability and safety of subcutaneous human immunoglobulin (octanorm) in patients with primary immunodeficiency diseases.","primaryOutcome":{"measure":"Number of Serious Bacterial Infections Per Person-Year on Treatment","timeFrame":"Primary Treatment Period (24 Weeks)","effectByArm":[{"arm":"Octanorm","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":5,"countries":["Russia"]},"refs":{"pmids":["32212944"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Respiratory Tract Infection","Condition Aggravated","Bronchitis","Dizziness","Food Poisoning"]}}